查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1628899

癌胚抗原市場，按性別、按應用、最終用戶、按國家和地區分類 - 2024-2032 年行業分析、市場規模、市場佔有率和預測

Carcinoembryonic Antigen Market, By Gender, By Application, By End-user, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 316 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

報告要點

2023年癌胚抗原市場規模為22.155億美元，2024年至2032年複合年成長率為6.50%。

癌胚抗原市場-市場動態

癌症發生率上升

預計癌症病例的增加將推動未來癌胚抗原市場的發展。異常細胞不受控制的發育和擴散是癌症的標誌。由於人口老化、遺傳傾向、環境污染物和生活方式的選擇，癌症變得越來越普遍。腫瘤標記癌胚抗原（CEA）用於追蹤癌症的病程和治療效果。例如，總部位於美國的政府間機構世界衛生組織 (WHO) 在 2024 年 2 月表示，預計 2050 年將出現約 3,500 萬新發癌症病例，比 2019 年預測的 2,000 萬例增加 77%。因此，由於癌症發生率的增加，癌胚抗原市場正在擴大。

癌胚抗原市場-關鍵見解

根據我們的研究分析師分享的分析，預計全球癌胚抗原市場在預測期內（2024-2032）每年將以 6.50% 左右的複合年成長率成長

根據性別細分，預計男性類別將在 2023 年顯示最大的市場佔有率

從應用細分來看，2023年胃腸癌是主導細分領域

按地區分類，北美是 2023 年的主要收入來源

癌胚抗原市場-細分分析：

全球癌胚抗原市場根據性別、應用、最終用戶和地區進行細分。

依應用，市場分為肺癌、胃腸道癌（大腸癌、食道癌、肝癌、胰臟癌、胃癌、肛門癌、膽囊癌）、乳癌、卵巢癌、攝護腺癌和甲狀腺癌。 2023年，市場以胃腸道癌症類別為主。在全球範圍內，結腸癌、胃癌和胰腺癌是最常見的腸癌類型。其高盛行率和侵襲性推動了對有效診斷和監測方法的需求，而 CEA 是這些疾病的關鍵生物標記。此外，由於風險隨著年齡的成長而增加，人口老化——特別是在已開發地區——導致胃腸道惡性腫瘤盛行率增加。這種人口趨勢進一步增加了對 CEA 檢測的需求，這進一步鞏固了胃腸道癌症領域的相關性。

癌胚抗原市場分為最終用戶部分，包括醫院、腫瘤診所、診斷實驗室、研究中心和學術機構。 2023 年醫院部門的收入為。癌症診斷、治療和監測的主要地點是醫院，通常使用 CEA 檢測。由於全球癌症發生率不斷上升，對監測和診斷工具的需求增加，醫院對 CEA 檢測的使用不斷增加。醫院經常使用經過訓練的工作人員和尖端的診斷工具，進一步促進了 CEA 檢測的準確和有效使用。對癌症患者的常規醫院監測和早期發現的關注有助於該細分市場的成長。

癌胚抗原市場-地理洞察

從地理來看，癌胚抗原市場廣泛分佈於北美、拉丁美洲、歐洲、亞太地區、中東和非洲地區。這些區域根據開展業務的國家進一步分類。

由於北美地區癌症發生率高、醫療保健系統完善以及研發支出龐大，該地區的癌胚抗原市場在全球佔據主導地位。由於早期癌症識別和監測對於成功治療至關重要，因此該地區的市場正在不斷成長。美國癌症協會預計，到 2023 年，北美將診斷出 190 萬新癌症病例。由於發生率高，CEA 和其他腫瘤標記的需求量很大。此外，許多主要的診斷公司，例如雅培實驗室和羅氏診斷公司，都總部位於北美，並不斷開發和擴大其產品線以滿足不斷成長的需求。

然而，未來幾年，由於癌症盛行率上升、醫療成本上升以及早期癌症檢測意識增強等因素，亞太地區癌胚抗原市場預計將大幅成長。中國、印度和日本由於人口眾多且癌症發生率較高，因此處於這一擴張的最前線。根據國際癌症研究機構 (IARC) 的數據，2020 年，亞洲約佔全球所有癌症病例的 49.3%。進一步推動該地區市場擴張的是政府加強醫療設施和鼓勵早期診斷檢測（例如 CEA）的計劃。

癌胚抗原市場-競爭格局：

癌胚抗原市場是由主要公司之間的激烈競爭推動的，包括 Quest Diagnostics、Thermo Fisher Scientific Inc.、Boster Biological Technology、Abcam Limited、Creative Diagnostics 和 F. Hoffmann-La Roche Ltd 等。這些公司投資於研發，以提高癌胚抗原測試的精確度和可負擔性，同時利用其廣泛的產品組合和強大的分銷網路。透過免疫測定和即時診斷的進步，新興企業也正在推動該產業的發展。此外，技術發展以及對早期癌症檢測和監測的日益重視正在推動市場需求，並為老牌和新興競爭對手打開大門。例如，2023 年 12 月，賽諾菲暫停了 tusamitamab ravtansine 的全球科學開發計畫。 3 期 CARMEN-LC03 試驗是這項決定的來源，該試驗評估了 tusamitamab ravtansine 作為單一療法與多西他賽對已接受治療的轉移性非鱗狀非小細胞肺癌 (NSCLC) 患者的治療效果。

最新進展：

2024 年4 月：著名的AI TechBio 業務和精準醫療先驅Caris DiscoveryTM（Caris Life Sciences(R) (Caris) 的研究部門）宣布與總部位於德國達姆施塔特的默克公司建立長期戰略合作夥伴關係。在美國和加拿大，以 EMD Serono 為名經營醫療保健業務的 Merck KGaA 將與 Caris DiscoveryTM 合作，加速為癌症患者尋找和開發優質抗體藥物偶聯物 (ADC)。

2024 年3 月：FDA 指定A2 Biotherapeutics Inc. 為A2B530 的孤兒藥，A2B530 是一種新型細胞療法，旨在治療生殖系雜合HLA-A02 陽性且腫瘤表達CEA 但不再表達HLA-A02 的結直腸癌患者。這一稱號鼓勵了藥物的開發。它透過強調大腸直腸癌解決這一特定患者群體中未滿足的主要需求的潛力，為結直腸癌治療的進展提供激勵。

2023 年7 月：為了同時獨立地從單一人血漿或血液樣本中確定丙型肝炎病毒(HCV) 抗原和抗體狀態，羅氏診斷印度公司推出了Elecsys HCV Duo，這是該國首個完全自動化的免疫測定法。這種創新的診斷技術簡化了醫療專業人員的程序並改善了患者的治療結果，代表了 HCV 識別的重大進步。

目錄

第1章：癌胚抗原市場概述

  • 研究範圍
  • 市場預估年份

第 2 章：執行摘要

  • 市場片段
    • 按性別分類的癌胚抗原市場片段
    • 按應用分類的癌胚抗原市場片段
    • 最終用戶的癌胚抗原市場片段
    • 按國家/地區分類的癌胚抗原市場片段
    • 按地區分類的癌胚抗原市場片段
  • 競爭洞察

第 3 章：癌胚抗原主要市場趨勢

  • 癌胚抗原市場促進因素
    • 市場促進因素的影響分析
  • 癌胚抗原市場限制
    • 市場限制影響分析
  • 癌胚抗原市場機會
  • 癌胚抗原市場未來趨勢

第 4 章：癌胚抗原產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第 5 章：癌胚抗原市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後影響分析
    • 表現最佳的市場區隔
    • 邊際成長市場區隔
    • 最寬鬆的市場區隔
    • 邊際損失市場區隔

第 6 章：癌胚抗原市場格局

  • 2023 年癌胚抗原市場佔有率分析
  • 按主要製造商分類的故障數據
    • 既有參與者分析
    • 新興參與者分析

第 7 章：癌胚抗原市場 - 按性別

  • 概述
    • 按性別分類的細分市場佔有率分析
    • 男性
    • 女性

第 8 章：癌胚抗原市場 - 按應用

  • 概述
    • 按應用分類的細分市場佔有率分析
    • 肺癌
    • 胃腸癌
      • 大腸直腸癌
      • 食道癌
      • 肝癌
      • 胰腺癌
      • 胃癌
      • 肛門癌
      • 膽囊癌
    • 乳癌
    • 卵巢癌
    • 攝護腺癌
    • 甲狀腺癌

第 9 章：癌胚抗原市場 - 按最終用戶

  • 概述
    • 按最終用戶分類的細分市場佔有率分析
    • 醫院
    • 腫瘤診所
    • 診斷實驗室
    • 研究中心和學術機構

第 10 章：癌胚抗原市場 - 按地理位置

  • 介紹
    • 按地理位置分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美癌胚抗原主要製造商
    • 北美市場規模和預測（按國家）
    • 北美市場規模與預測（按性別）
    • 北美市場規模和預測（按應用）
    • 北美市場規模和預測（按最終用戶）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲癌胚抗原主要製造商
    • 歐洲市場規模和預測（按國家）
    • 歐洲市場規模與預測（按性別）
    • 歐洲市場規模和預測（按應用）
    • 歐洲市場規模和預測（按最終用戶）
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區癌胚抗原主要生產商
    • 亞太地區市場規模與預測（按國家）
    • 亞太地區市場規模與預測（依性別）
    • 亞太地區市場規模與預測（按應用）
    • 亞太地區市場規模和預測（按最終用戶）
    • 印度
    • 中國
    • 韓國
    • 日本
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲癌胚抗原主要製造商
    • 拉丁美洲市場規模與預測（按國家）
    • 拉丁美洲市場規模與預測（按性別）
    • 拉丁美洲市場規模與預測（按應用）
    • 拉丁美洲市場規模和預測（按最終用戶）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲癌胚抗原主要生產商
    • 中東和非洲市場規模及預測（按國家）
    • 中東和非洲市場規模及預測（按性別）
    • 中東和非洲市場規模及預測（按應用）
    • 中東和非洲市場規模和預測（按最終用戶）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 的其餘部分

第 11 章：主要供應商分析-癌胚抗原產業

  • 競爭儀表板
  • 公司簡介
    • Boster Biological Technology
    • Abcam Limited
    • Creative Diagnostics
    • Aviva Systems Biology Corporation
    • AdvaCare Pharma
    • F. Hoffmann-La Roche Ltd.
    • Thermo Fisher Scientific Inc.
    • Omega Diagnostics Ltd.
    • Medix Biochemica
    • RayBiotech, Inc.
    • Diazyme Laboratories Inc.
    • Quest Diagnostics Incorporated
    • Others

第 12 章：360 度分析師視角

第 13 章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV4432

REPORT HIGHLIGHT

Carcinoembryonic Antigen Market size was valued at USD 2,215.5 Million in 2023, expanding at a CAGR of 6.50% from 2024 to 2032.

The endodermal epithelial cells of the embryo contain carcinoembryonic antigen (CEA). The fluids of the fetus, embryo, and gastrointestinal tract contain a glycoprotein called carcinoembryonic antigen. Carcinoembryonic antigen is also present in trace amounts in the blood, gastrointestinal cells, and colon mucosal cells. Additionally, the test can be used to diagnose and treat cancers like ovarian, lung, liver, colorectal, gastrointestinal, or colon cancers, as well as breast cancer. The market is expected to rise as a result of rising cancer incidence, an ageing population, and increased awareness. Over the past ten years, there has been a notable increase in the yearly number of cancer diagnoses worldwide. Additionally, as life expectancy rises, more people will receive a diagnosis during their lifetime, which will fuel market expansion.

Carcinoembryonic Antigen Market- Market Dynamics

Rising Incidence of Cancer

It is anticipated that the rising cases of cancer will fuel the market for carcinoembryonic antigens in the future. Uncontrolled development and spread of aberrant cells is a hallmark of cancer. Cancer is becoming common as a result of ageing populations, genetic predispositions, environmental pollutants, and lifestyle choices. The tumour marker carcinoembryonic antigen (CEA) is used to track the course of cancer and the efficacy of treatment. For instance, the World Health Organization (WHO), an intergovernmental agency based in the United States, stated in February 2024 that around 35 million new cases of cancer are expected to occur in 2050, a 77% increase from the 20 million cases forecast in 2022. Thus, the carcinoembryonic antigen market is expanding due to the increase in cancer incidence.

Carcinoembryonic Antigen Market- Key Insights

As per the analysis shared by our research analyst, the global Carcinoembryonic Antigen Market is estimated to grow annually at a CAGR of around 6.50% over the forecast period (2024-2032)

Based on gender segmentation, the male category was predicted to show the maximum market share in the year 2023

Based on application segmentation, the gastrointestinal cancer was the leading segment in 2023

On the basis of region, North America was the leading revenue generator in 2023

Carcinoembryonic Antigen Market- Segmentation Analysis:

The Global Carcinoembryonic Antigen Market is segmented on the basis of Gender, Application, End-user, and Region.

By application, the market is divided into Lung cancer, Gastrointestinal cancer (Colorectal cancer, Esophageal cancer, Liver cancer, Pancreatic cancer, Stomach cancer, Anal cancer, Gall bladder cancer), Breast cancer, Ovarian cancer, Prostate cancer, and Thyroid cancer. In 2023, the market was dominated by the gastrointestinal cancer category. Globally, colon, stomach, and pancreatic cancers are among the most common types of intestinal cancers. The need for efficient diagnostic and monitoring methods is fueled by their high prevalence and aggressive nature, with CEA acting as a crucial biomarker for these disorders. Furthermore, because the risk increases with age, the ageing population-especially in developed regions-contributes to the increased prevalence of gastrointestinal malignancies. The demand for CEA testing is further increased by this demographic trend, which further solidifies the gastrointestinal cancer segment's relevance.

The market for carcinoembryonic antigens is divided into end-user segments, including Hospitals, Oncology clinics, Diagnostic laboratories, Research centres and academic institutes. Revenue for the hospitals' segment in 2023 was. The main locations for cancer diagnosis, treatment, and surveillance are hospitals, where CEA testing is commonly used. Hospital usage of CEA tests is increasing as a result of the increased demand for monitoring and diagnostic tools due to the rising incidence of cancer worldwide. The accurate and effective use of CEA testing is further facilitated by hospitals' frequent access to trained staff and cutting-edge diagnostic tools. The focus on routine hospital monitoring and early detection of cancer patients contributes to the segment's growth.

Carcinoembryonic Antigen Market- Geographical Insights

Geographically, the Carcinoembryonic Antigen Market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

The market for carcinoembryonic antigen in North America is dominated worldwide due to the region's high cancer incidence, sophisticated healthcare system, and significant R&D expenditures. Due to the fact that early cancer identification and monitoring are essential for successful treatment, the market in this region is growing. In 2023, the American Cancer Society projected that 1.9 million new cases of cancer will be diagnosed in North America. CEA and other tumour markers are in high demand due to this high incidence rate. Furthermore, a number of major diagnostics companies, such as Abbott Laboratories and Roche Diagnostics, are based in North America and are constantly developing and broadening their product lines to meet this rising demand.

However, over the upcoming years, the carcinoembryonic antigen market in the Asia-Pacific region is expected to rise significantly due to factors such as rising cancer prevalence, rising healthcare costs, and increased awareness of early cancer detection. China, India, and Japan are at the forefront of this expansion because of their sizable populations and greater rates of cancer. In 2020, Asia accounted for around 49.3% of all cancer cases worldwide, as per the International Agency for Research on Cancer (IARC). Further driving market expansion in the area are government programs to enhance healthcare facilities and encourage early diagnostic testing, such as CEA.

Carcinoembryonic Antigen Market- Competitive Landscape:

The carcinoembryonic antigen market is driven by fierce competition between major firms, including Quest Diagnostics, Thermo Fisher Scientific Inc., Boster Biological Technology, Abcam Limited, Creative Diagnostics, and F. Hoffmann-La Roche Ltd, among others. These companies invest in R&D to improve the precision and affordability of carcinoembryonic antigen tests while utilizing their broad portfolios and robust distribution networks. Through advancements in immunoassays and point-of-care diagnostics, emerging businesses are also boosting the industry. Furthermore, technical developments and the growing emphasis on early cancer detection and monitoring are driving market demand and opening doors for both established and up-and-coming competitors. For instance, in December 2023, the global scientific development project for tusamitamab ravtansine is being halted by Sanofi. The Phase 3 CARMEN-LC03 trial, which evaluates tusamitamab ravtansine as a monotherapy in comparison to docetaxel in patients with metastatic non-squamous non-small cellular lung cancer (NSCLC) who have already received treatment, is the source of this decision.

Recent Developments:

April 2024: The renowned AI TechBio business and precision medicine pioneer Caris DiscoveryTM, the research arm of Caris Life Sciences(R) (Caris), announced a long-term strategic partnership with Merck KGaA, headquartered in Darmstadt, Germany. In the United States and Canada, Merck KGaA, which operates its healthcare business under the name EMD Serono, will partner with Caris DiscoveryTM to accelerate the search for and development of superior antibody-drug conjugates (ADC) for cancer patients.

March 2024: The FDA designated A2 Biotherapeutics Inc. as an orphan medication for A2B530, a new cell therapy designed to treat colorectal cancer in patients with germline heterozygous HLA-A02 positivity whose tumours express CEA but no longer express HLA-A02. This designation encourages the development of the medication. It provides incentives for progress in the treatment of colorectal cancer by highlighting its potential to address a major unmet need in this particular patient population.

July 2023: To determine the hepatitis C virus (HCV) antigen and antibody status simultaneously and independently from a single human plasma or blood sample, Roche Diagnostics India introduced the Elecsys HCV Duo, the country's first completely automated immunoassay. This innovative diagnostic technology simplifies the procedure for medical professionals and improves patient outcomes, representing a major advancement in HCV identification.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Boster Biological Technology
  • Abcam Limited
  • Creative Diagnostics
  • Aviva Systems Biology Corporation
  • AdvaCare Pharma
  • F. Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific Inc.
  • Omega Diagnostics Ltd.
  • Medix Biochemica
  • RayBiotech, Inc.
  • Diazyme Laboratories Inc.
  • Quest Diagnostics Incorporated
  • Others

GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET, BY GENDER- MARKET ANALYSIS, 2019 - 2032

  • Male
  • Female

GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

  • Lung cancer
  • Gastrointestinal cancer
  • Colorectal cancer
  • Esophageal cancer
  • Liver cancer
  • Pancreatic cancer
  • Stomach cancer
  • Anal cancer
  • Gall bladder cancer
  • Breast cancer
  • Ovarian cancer
  • Prostate cancer
  • Thyroid cancer

GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Oncology clinics
  • Diagnostic laboratories
  • Research centres and academic institutes

GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Carcinoembryonic Antigen Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Carcinoembryonic Antigen Market Snippet by Gender
    • 2.1.2. Carcinoembryonic Antigen Market Snippet by Application
    • 2.1.3. Carcinoembryonic Antigen Market Snippet by End-user
    • 2.1.4. Carcinoembryonic Antigen Market Snippet by Country
    • 2.1.5. Carcinoembryonic Antigen Market Snippet by Region
  • 2.2. Competitive Insights

3. Carcinoembryonic Antigen Key Market Trends

  • 3.1. Carcinoembryonic Antigen Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Carcinoembryonic Antigen Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Carcinoembryonic Antigen Market Opportunities
  • 3.4. Carcinoembryonic Antigen Market Future Trends

4. Carcinoembryonic Antigen Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Carcinoembryonic Antigen Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Carcinoembryonic Antigen Market Landscape

  • 6.1. Carcinoembryonic Antigen Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Carcinoembryonic Antigen Market - By Gender

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Gender, 2023 & 2032 (%)
    • 7.1.2. Male
    • 7.1.3. Female

8. Carcinoembryonic Antigen Market - By Application

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Application, 2023 & 2032 (%)
    • 8.1.2. Lung cancer
    • 8.1.3. Gastrointestinal cancer
      • 8.1.3.1. Colorectal cancer
      • 8.1.3.2. Esophageal cancer
      • 8.1.3.3. Liver cancer
      • 8.1.3.4. Pancreatic cancer
      • 8.1.3.5. Stomach cancer
      • 8.1.3.6. Anal cancer
      • 8.1.3.7. Gall bladder cancer
    • 8.1.4. Breast cancer
    • 8.1.5. Ovarian cancer
    • 8.1.6. Prostate cancer
    • 8.1.7. Thyroid cancer

9. Carcinoembryonic Antigen Market - By End-user

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End-user, 2023 & 2032 (%)
    • 9.1.2. Hospitals
    • 9.1.3. Oncology clinics
    • 9.1.4. Diagnostic laboratories
    • 9.1.5. Research centres and academic institutes

10. Carcinoembryonic Antigen Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Carcinoembryonic Antigen Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Carcinoembryonic Antigen Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.8. France
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. France Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.3.8.4. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.8.5. France Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.9. Italy
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. Italy Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.3.9.4. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.9.5. Italy Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.10. Spain
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. United Kingdom Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.3.10.4. United Kingdom Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.10.5. United Kingdom Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.11. United Kingdom
      • 10.3.11.1. Overview
      • 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.3. United Kingdom Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.3.11.4. United Kingdom Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.11.5. United Kingdom Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.12. Russia
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Russia Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Russia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.13. Netherlands
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Netherlands Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Netherlands Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.14. Sweden
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Sweden Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Sweden Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.15. Poland
      • 10.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.2. Poland Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.3.15.3. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Poland Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.16. Rest of Europe
      • 10.3.16.1. Overview
      • 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.16.3. Rest of the Europe Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.3.16.4. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.16.5. Rest of the Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Carcinoembryonic Antigen Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.9. South Korea
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. South Korea Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.4.9.4. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.9.5. South Korea Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.10. Japan
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. Japan Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.4.10.4. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.10.5. Japan Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Carcinoembryonic Antigen Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Carcinoembryonic Antigen Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Carcinoembryonic Antigen Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Boster Biological Technology
    • 11.2.2. Abcam Limited
    • 11.2.3. Creative Diagnostics
    • 11.2.4. Aviva Systems Biology Corporation
    • 11.2.5. AdvaCare Pharma
    • 11.2.6. F. Hoffmann-La Roche Ltd.
    • 11.2.7. Thermo Fisher Scientific Inc.
    • 11.2.8. Omega Diagnostics Ltd.
    • 11.2.9. Medix Biochemica
    • 11.2.10. RayBiotech, Inc.
    • 11.2.11. Diazyme Laboratories Inc.
    • 11.2.12. Quest Diagnostics Incorporated
    • 11.2.13. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us